Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03364049 · ClinicalTrials.gov registry record · Phase 1
Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03364049 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 33 participants.
The verdict
NCT03364049, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purposes of this study are to determine the safety and tolerability of MK-7162 when administered in combination with pembrolizumab (MK-3475) and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-7162 when administered in combination with pembrolizumab.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG MK-7162
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-12-06 |
| Est. Completion | 2020-10-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03364049
The ClinicalTrials.gov registry entry for NCT03364049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03364049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03364049 about?
NCT03364049 is a clinical study titled "Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)". The purposes of this study are to determine the safety and tolerability of MK-7162 when administered in combination with pembrolizumab (MK-3475) and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-7162 when administered in combination with pembrolizumab.
What is the current status of trial NCT03364049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2017-12-06. Estimated completion is 2020-10-19.
What interventions are being tested in trial NCT03364049?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), MK-7162 (DRUG).
Who is sponsoring clinical trial NCT03364049?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.